AnthemBiosciences made a strong debut on the Indian stock market today, July 21, 2025. The company shares opened at ₹723.05 on the NSE and ₹723.10 on the BSE a premium of nearly 27% over the issue price of ₹570. This listing was in line with expectations as hinted by the grey market premium (GMP).
Anthem
Biosciences, known for its fermentation-based APIs, saw huge demand
during its IPO. The public offer was oversubscribed 63.86 times, with
QIBs subscribing 182.65 times, NIIs 42.36 times, and retail investors 5.64
times. This shows strong investor interest, especially from institutions.
As of 12:25 PM,
the share price was trading at ₹728.90 on the BSE, up 0.80% from the listing
price and 27.88% higher than the IPO price.
Buy, Sell or Hold: What Do Experts Say?
1. For
Short-Term Investors
Mahesh M. Ojha from Hensex Securities suggests that short-term investors
who received allotment should book partial profits. “Gaining more than
25% on listing is significant. Booking some profit allows you to reduce risk,”
he said.
2. For
Long-Term Investors
Ojha adds, “Long-term investors should watch for sustainable margins, growth in
global clients, and the innovation pipeline. The fundamentals are strong, but
future performance matters.”
3. For Those
Who Missed the IPO
“If you missed the IPO, wait for a few sessions. Once the stock stabilizes, you
might find a better entry point,” Ojha recommends.
Valuation and Future Outlook
Prashanth Tapse
of Mehta Equities says, “Valuations may seem high post-listing, but they’re
backed by solid fundamentals, unique capabilities, and a promising
future in the CRDMO sector.”
Tapse advises
investors to "Hold" for the long term. He sees a short-term
target of ₹900 and a long-term potential beyond ₹1,000. If the share
dips to ₹650–680, he says it would be a great entry point for new
investors.
Anthem Biosciences IPO Snapshot
| Details | Info |
|---|---|
| IPO Price | ₹570 per share |
| Listing Price (NSE/BSE) | ₹723.05 / ₹723.10 |
| Listing Premium | ~27% |
| Subscription Rate | 63.86 times overall |
| QIB Subscription | 182.65 times |
| NII Subscription | 42.36 times |
| Retail Subscription | 5.64 times |
| Current Price (12:25 PM) | ₹728.90 |
Final Takeaway: What Should You Do?
- If you got allotment: Book some profits and hold the
rest if you're confident in long-term prospects.
- If you missed the IPO: Wait for a dip; ₹650–680 is a
potential accumulation zone.
- Long-term investors: Anthem Biosciences is a
promising bet in the fast-growing CRDMO sector. Holding for targets above
₹1,000 could be rewarding.
Disclaimer:
This article is based on analyst views and market data. Always consult a
SEBI-registered advisor before making investment decisions.
